Antibiotics Classes

Why This Matters

Antibiotics don't just "kill bacteria." They target specific cellular machinery, and understanding which machinery determines everything from spectrum of activity to resistance patterns. You're being tested on your ability to connect mechanism of action to clinical application: Why does vancomycin work against MRSA when penicillin doesn't? Why do we combine certain antibiotics for synergy? These questions require you to think beyond memorization.

The antibiotic classes below demonstrate core principles of selective toxicity, ribosomal targeting, cell wall architecture, and resistance evolution. When you encounter exam questions about treatment choices or resistance mechanisms, you need to instantly recall which cellular target each class hits and why that matters for Gram-positive versus Gram-negative coverage. Don't just memorize drug names; know what each class teaches you about bacterial vulnerability.

---

Cell Wall Synthesis Inhibitors

The bacterial cell wall is a unique target because human cells lack this structure entirely, making these antibiotics highly selective. Beta-lactams and glycopeptides both disrupt peptidoglycan synthesis, but they bind to different molecular targets, which explains their different resistance profiles.

Beta-Lactams (Penicillins, Cephalosporins, Carbapenems)

• Inhibit transpeptidase enzymes (PBPs): prevents cross-linking of peptidoglycan, causing osmotic lysis and cell death
• Spectrum varies by generation: natural penicillins target mainly Gram-positives; successive generations of cephalosporins broaden Gram-negative coverage (while often losing some Gram-positive activity); carbapenems have the broadest spectrum and are reserved for multi-drug resistant (MDR) infections
• Beta-lactamase production is the primary resistance mechanism. Bacteria produce enzymes that hydrolyze the beta-lactam ring, inactivating the drug. This is why we pair some beta-lactams with beta-lactamase inhibitors (e.g., amoxicillin-clavulanate) to restore activity
• MRSA resistance works differently: it involves acquisition of the mecA gene, which encodes an altered PBP (PBP2a) with low affinity for beta-lactams. The drug can't bind its target, so it can't work

Glycopeptides (Vancomycin)

• Binds the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursors. Rather than inhibiting an enzyme, it physically sequesters the building blocks so transpeptidases can't access them
• Gram-positive only: vancomycin is a large molecule that cannot penetrate the outer membrane of Gram-negatives, which is why it's the go-to for MRSA
• "Red man syndrome" occurs with rapid IV infusion. This is a direct histamine release reaction, not a true IgE-mediated allergy. Slowing the infusion rate typically resolves it
• Vancomycin resistance (VRE): some enterococci modify their peptidoglycan precursors to D-Ala-D-Lac, which vancomycin can't bind. This is a fundamentally different resistance strategy than what you see with beta-lactams

---

Protein Synthesis Inhibitors: 30S Ribosomal Subunit

Bacterial ribosomes (70S = 30S + 50S) differ structurally from human ribosomes (80S = 40S + 60S), allowing selective targeting. Drugs binding the 30S subunit interfere with the initiation complex or cause mRNA misreading.

Aminoglycosides

• Bind the 30S subunit irreversibly, causing misreading of mRNA. The resulting faulty proteins get inserted into the cell membrane, damaging its integrity. This is why aminoglycosides are bactericidal despite being "protein synthesis inhibitors"
• Aerobic Gram-negative coverage: aminoglycosides require oxygen-dependent transport to enter the cell, so they're ineffective against anaerobes and have limited activity against facultative anaerobes growing in low-oxygen conditions
• Nephrotoxicity and ototoxicity are the major dose-limiting toxicities. These drugs accumulate in renal tubular cells and the inner ear. Trough levels are monitored to minimize damage
• Often combined with beta-lactams for synergistic killing: the beta-lactam damages the cell wall, allowing better aminoglycoside penetration. This combination is used for serious infections like endocarditis

Tetracyclines

• Bind the 30S subunit reversibly, blocking aminoacyl-tRNA from entering the ribosomal A site. This halts peptide elongation without causing misreading, making tetracyclines bacteriostatic
• Broad-spectrum including atypicals: effective against Chlamydia, Mycoplasma, and Rickettsia because tetracyclines penetrate well into cells where these intracellular pathogens hide
• Contraindicated in pregnancy and children under 8: deposits in developing bones and teeth, causing permanent discoloration. Resistance via efflux pumps (bacteria actively pump the drug out) and ribosomal protection proteins is widespread

---

Protein Synthesis Inhibitors: 50S Ribosomal Subunit

Drugs targeting the 50S subunit block later steps in translation, either peptide bond formation or translocation. These tend to be bacteriostatic and cover atypical pathogens well.

Macrolides (Azithromycin, Erythromycin)

• Bind the 50S subunit, blocking translocation (the ribosome's movement along the mRNA). This is bacteriostatic at normal concentrations
• Respiratory infection workhorses: cover Streptococcus pneumoniae plus atypicals like Mycoplasma pneumoniae and Legionella pneumophila, making them ideal for empiric treatment of community-acquired pneumonia
• Penicillin allergy alternative: commonly prescribed when beta-lactams are contraindicated. Azithromycin's long tissue half-life allows convenient short-course dosing (the classic "Z-pack")
• Resistance occurs primarily through methylation of the 23S rRNA binding site (encoded by erm genes), which also confers resistance to lincosamides (clindamycin). This is called MLS$_B$ resistance

Oxazolidinones (Linezolid)

• Bind the 50S subunit at a unique site, preventing formation of the 70S initiation complex. Translation is blocked before it even starts, which is a different step than what macrolides target
• Reserved for resistant Gram-positives: effective against MRSA and VRE when vancomycin fails or can't be used
• Myelosuppression with prolonged use (especially thrombocytopenia): monitor CBC weekly. Also inhibits monoamine oxidase, so concurrent use with MAOIs or serotonergic drugs risks serotonin syndrome

---

DNA Targeting Antibiotics

These classes attack bacterial DNA directly, either by disrupting replication machinery or damaging the DNA itself. Because DNA processes are fundamental, resistance often requires mutations in essential enzymes rather than simple enzyme acquisition.

Fluoroquinolones (Ciprofloxacin, Levofloxacin)

• Inhibit DNA gyrase (primarily in Gram-negatives) and topoisomerase IV (primarily in Gram-positives): these enzymes manage DNA supercoiling and chromosome segregation during replication. Blocking them is bactericidal
• Broad-spectrum oral option: covers both Gram-positives and Gram-negatives with excellent oral bioavailability, making them useful for outpatient treatment of UTIs, respiratory infections, and GI infections
• Black box warnings include tendon rupture (especially the Achilles tendon in older adults and those on corticosteroids), peripheral neuropathy, and CNS effects. Resistance via target-site mutations in the gyrase/topoisomerase genes is increasing, which is why fluoroquinolones should not be used as first-line agents when alternatives exist

Nitroimidazoles (Metronidazole)

• Forms toxic free radicals inside anaerobic organisms: the drug's nitro group gets reduced by low-redox-potential electron carriers found only in anaerobes. The resulting reactive intermediates damage DNA and cause strand breakage
• Anaerobe and protozoa specialist: drug of choice for Clostridioides difficile colitis (oral route), Bacteroides fragilis, Giardia lamblia, and Trichomonas vaginalis
• Disulfiram-like reaction with alcohol: metronidazole inhibits aldehyde dehydrogenase, so patients must avoid alcohol during treatment and for 48 hours after. Resistance rates remain relatively low

---

Membrane and Metabolic Pathway Disruptors

These classes don't fit the classic "cell wall or ribosome" categories. They target the cell membrane directly or block essential metabolic pathways.

Polymyxins (Colistin, Polymyxin B)

• Disrupt outer membrane integrity: bind to the lipid A component of LPS and insert into the membrane like detergents, causing leakage of cellular contents and death
• Last-resort Gram-negative coverage: effective against MDR Pseudomonas aeruginosa and Acinetobacter baumannii when carbapenems and other options have failed
• Significant nephrotoxicity and neurotoxicity: reserved for situations where no safer alternative exists. Emerging resistance through mcr genes (which modify lipid A to reduce polymyxin binding) is a serious public health concern because these are often our last line of defense

Sulfonamides and Trimethoprim

• Sulfonamides block dihydropteroate synthase and trimethoprim blocks dihydrofolate reductase. Both enzymes are in the folate synthesis pathway, which bacteria must carry out de novo. Humans get folate from their diet, so these drugs are selectively toxic
• TMP-SMX (Bactrim) combines both drugs to create a sequential blockade of the folate pathway. Hitting two steps in the same pathway produces synergistic bactericidal activity, even though each drug alone is only bacteriostatic
• Sulfa allergies are among the most commonly reported drug allergies. Also watch for hematological effects (megaloblastic anemia, especially in folate-deficient patients) and hyperkalemia with trimethoprim

---

Quick Reference Table

---

Self-Check Questions

1. Both aminoglycosides and tetracyclines bind the 30S ribosomal subunit. Why is one bactericidal and the other bacteriostatic?

2. A patient with a severe penicillin allergy presents with community-acquired pneumonia. Which antibiotic class would you choose, and what mechanism makes it effective against atypical respiratory pathogens?

3. Compare and contrast beta-lactam resistance (via beta-lactamases and PBP modification) with vancomycin resistance (via D-Ala-D-Lac modification). How do these different mechanisms reflect each drug's binding target?

4. Why is metronidazole ineffective against aerobic bacteria, and what does this tell you about its mechanism of action?

5. If asked to design a combination therapy for a serious Gram-positive infection, which two classes would you pair for synergy, and what cellular targets would you be hitting simultaneously?